Brokers Set Expectations for AARD FY2027 Earnings

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – HC Wainwright issued their FY2027 EPS estimates for Aardvark Therapeutics in a report issued on Monday, July 20th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($1.98) for the year. HC Wainwright has a “Neutral” rating and a $6.00 price objective on the stock. The consensus estimate for Aardvark Therapeutics’ current full-year earnings is ($3.48) per share.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) earnings per share for the quarter.

A number of other research firms also recently issued reports on AARD. BTIG Research downgraded Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings upgraded Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. Finally, B. Riley Financial decreased their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $16.30.

Aardvark Therapeutics Stock Up 6.6%

AARD stock opened at $6.48 on Tuesday. The company has a market cap of $141.78 million, a price-to-earnings ratio of -2.02 and a beta of 3.93. The business has a fifty day simple moving average of $4.82 and a 200-day simple moving average of $7.37. Aardvark Therapeutics has a 52 week low of $3.35 and a 52 week high of $17.94.

Institutional Trading of Aardvark Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AARD. Renaissance Technologies LLC acquired a new stake in Aardvark Therapeutics in the 1st quarter valued at $267,000. Bank of New York Mellon Corp lifted its stake in shares of Aardvark Therapeutics by 30.8% during the first quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock worth $111,000 after purchasing an additional 6,905 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Aardvark Therapeutics during the fourth quarter worth about $335,000. Superstring Capital Management LP purchased a new stake in shares of Aardvark Therapeutics in the fourth quarter worth about $912,000. Finally, Millennium Management LLC boosted its position in shares of Aardvark Therapeutics by 51.2% in the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company’s stock worth $6,344,000 after buying an additional 163,717 shares during the period.

Aardvark Therapeutics News Summary

Here are the key news stories impacting Aardvark Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Neutral rating and $6.00 price target on Aardvark Therapeutics, while issuing earnings estimates for 2026-2027. The firm also nudged its Q4 2026 EPS estimate higher, which may have helped sentiment around the stock. MarketBeat AARD report
• Neutral Sentiment: HC Wainwright’s forecasts still point to continuing losses over the next several quarters, with FY2026 EPS estimated at ($3.80) and FY2027 at ($1.98), underscoring that Aardvark remains a pre-profit biotech story. MarketBeat AARD report
• Negative Sentiment: Investor focus is still being weighed down by the FDA clinical hold on Aardvark’s lead Prader-Willi Syndrome candidate, a development that previously triggered a sharp selloff and continues to create uncertainty around the company’s pipeline. PR Newswire article

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.